Form 4: Alnylam Pharmaceuticals Executive Sells Shares After Performance-Based Stock Unit Vesting

Alnylam Pharmaceuticals' EVP, Chief Commercial Officer, Tolga Tanguler, sold shares to cover tax obligations after a performance-based stock unit vested.

Summary

• Tolga Tanguler, EVP and Chief Commercial Officer of Alnylam Pharmaceuticals, received 3,000 shares of common stock on November 25, 2024, as part of a performance-based stock unit (PSU) that vested.
• The PSU vested due to the company publicly reporting FDA acceptance of a new drug application for a therapeutic to treat ATTR amyloidosis with cardiomyopathy, following positive Phase 3 clinical trial results.
• On November 26, 2024, Mr. Tanguler sold a total of 1,570 shares to cover tax obligations related to the vesting of the PSU.
• The sales occurred in multiple transactions at weighted average prices ranging from $247.77 to $252.27 per share.
• Following these transactions, Mr. Tanguler directly owns 13,191 shares of Alnylam common stock.

Sentiment

Score: 6

Explanation: The document reflects a positive milestone achievement (FDA acceptance) but also includes an executive stock sale, which can be viewed neutrally or slightly negatively. The overall sentiment is moderately positive.

Positives

• The vesting of the performance-based stock unit indicates the achievement of a significant milestone for Alnylam, specifically the FDA acceptance of a new drug application.
• The positive Phase 3 clinical trial results for the ATTR amyloidosis treatment are a positive development for the company.

Negatives

• The sale of shares by an executive, even for tax purposes, could be perceived negatively by some investors.

Risks

• Executive stock sales, even for tax obligations, can sometimes create short-term price volatility.
• The market's reaction to executive stock sales can be unpredictable.

Management Comments

• The shares were issued to the reporting person upon vesting of one-third of the shares subject to the PSU based on the issuer publicly reporting FDA acceptance of a new drug application submitted for regulatory approval for a therapeutic to treat ATTR amyloidosis with cardiomyopathy after receipt of a positive, statistically significant result on a clinical outcomes endpoint from a Phase 3 study, as determined by The People, Culture and Compensation Committee of the Issuer Board of Directors on November 22, 2024.

Industry Context

The vesting of the PSU and subsequent stock sale are related to the company's progress in developing a treatment for ATTR amyloidosis, a significant area of focus in the pharmaceutical industry. The FDA acceptance of the new drug application is a key milestone in the drug development process.

Comparison to Industry Standards

• Executive compensation packages often include performance-based stock units that vest upon achieving specific milestones, which is a common practice in the biotech and pharmaceutical industries.
• The sale of shares to cover tax obligations is a standard procedure for executives receiving stock-based compensation.
• Companies like Ionis Pharmaceuticals and Arrowhead Pharmaceuticals also focus on RNA-based therapeutics and have similar executive compensation structures.

Stakeholder Impact

• Shareholders may view the vesting of the PSU as a positive sign of the company's progress.
• The stock sale by the executive could cause short-term price fluctuations.

Key Dates

Keywords

Alnylam Pharmaceuticals, Tolga Tanguler, stock sale, performance-based stock unit, PSU, FDA approval, ATTR amyloidosis, executive compensation, insider trading, clinical trial